生物科技公司Castle Biosciences, Inc.（纳斯达克股票代码：CSTL）今日盘前股价大跌6.13%，主要原因是该公司公布的2025年第一季度财报未能达到市场预期。
根据最新发布的财报，Castle Biosciences第一季度调整后每股亏损为0.20美元，远低于分析师平均预期的0.07美元亏损。虽然公司第一季度营收同比增长20.6%，达到8799万美元，超过了分析师预期的8034万美元，但仍未能抵消盈利方面的失望表现。此外，公司本季度净亏损高达2585万美元，进一步加剧了投资者的担忧。
尽管Castle Biosciences今年以来股价已下跌27.4%，但分析师对该公司的前景仍保持乐观态度。目前，分析师对该公司股票的平均评级为"强力买入"，12个月目标价中位数为40.00美元。然而，考虑到本次财报业绩不佳，投资者可能需要重新评估公司的短期增长前景。随着市场对Castle Biosciences第一季度业绩的消化，未来几个交易日内该股可能会面临进一步的波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.